Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences reported Q3 2026 revenue of $33.5 million, up 68% year over year, with consumables revenue up 79% to $17.8 million and gross margin reaching a record 61.5%. The company raised FY2026 revenue guidance to $121 million–$123 million from $116 million–$120 million, while net loss widened to $13.3 million from $8.0 million amid higher investment; management expects TAP revenue to decline sequentially in Q4. Alamar reported $231.5 million in cash, cash equivalents, short-term investments and restricted cash at Sept. 30, and highlighted UK Biobank and GSK studies covering a combined 140,000-plus samples, alongside a planned FDA marketing authorization submission for ARGO HT/DX by the end of 2027.

Analysis

The key underwriting question is whether ALMR is converting episodic project work into repeatable instrument-driven consumables revenue. Q3’s mix supports that transition, but the unusually strong TAP contribution flatters the quarter; management’s Q4 sequential TAP decline and cautious outlook create near-term estimate and sentiment risk even if consumables continue growing. Treat the raised annual outlook as a better demand signal than the headline growth rate, not proof that quarterly growth is linear.

Over the next 1–3 months, watch consumables growth and instrument placements separately from TAP. The 100-instrument goal and >$400,000 pull-through target are the more useful tests of recurring economics; longer sales cycles make placements lumpy. Gross margin expansion is plausible as consumables scale, but Q3’s record is mix- and utilization-sensitive, while operating expenses are growing rapidly and losses are widening. Cash provides capacity to invest, not evidence of a near-term path to profitability.

The UK Biobank and GSK programs are credibility and funnel assets before they are clearly material recurring revenue: samples process over multiple quarters, with timing and contribution undisclosed. Their second-order value is broader adoption and follow-on studies, but that depends on usable data and conversion into paid work. Competition from established proteomics platforms remains a constraint; scientific claims of differentiation need independent replication and commercial conversion. The clinical opportunity is materially longer-dated: FDA submission is targeted for end-2027, with authorization and partner-developed tests still subsequent hurdles. Consensus may overvalue validation headlines while underweighting execution time and dilution/expense risk; valuation is not supplied, so the growth profile alone does not establish attractive entry pricing.

Key Decisions for Investors

• Do not chase the validation headlines without valuation and post-call price context. Keep ALMR on a catalyst watchlist; reassess after Q4 results, focusing on consumables growth, instrument placements, and whether full-year targets are met despite TAP normalization.
• Treat any Q4 sequential revenue softness as potentially mix/timing-related, not automatically a demand break. Falsify that view if consumables growth slows materially or the company misses its instrument-placement and pull-through targets.
• Avoid underwriting 61.5% gross margin as a run rate. Track quarterly mix and gross margin alongside operating-expense growth; sustained margin deterioration or continued expense acceleration without recurring-revenue leverage would weaken the long thesis.
• Monitor UK Biobank processing ramp and GSK study commencement/conversion over 2027; do not capitalize undisclosed project economics as contracted recurring revenue. For GSK, regard the collaboration as strategic validation rather than a demonstrated material financial catalyst.